Candel Therapeutics, Inc.

NASDAQ•CADL

CEO: Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.

板块: Healthcare

行业: Biotechnology

上市日期: 2021-07-27

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

联系方式

117 Kendrick Street, Suite 450, Needham, MA, 02494, United States

617-916-5445

www.candeltx.com

市值

$279.99M

市盈率 (TTM)

-7.3

19.2

股息率

52周最高

$7.25

52周最低

$4.34

52周范围

26%

排名58Top 85.6%

2.3

F-Score

改良版 Piotroski 分析

基于 6 年期基本面

疲弱 • 2.3 / 9 分

评分区间 (0-9)

8-9: 价值优异

6-7: 基本面强劲

4-5: 整体稳健

0-3: 表现疲弱

数据范围: 2020-2025

财务仪表盘

Q4 2025 数据

营业收入

$0.00+0.00%

近4季度走势

每股收益

-$0.54+0.00%

近4季度走势

自由现金流

-$10.98M+0.00%

近4季度走势

2025 Annual 财报亮点

核心亮点

Net Loss Narrows Significantly Net loss decreased $16,995 K to $(38,182) K for 2025, reflecting reduced warrant liability impact.

Aglatimagene Prostate Success Phase 3 DFS endpoint met for aglatimagene plus radiation (HR 0.70); median DFS not reached.

R&D Investment Increases Research and development expenses increased $11.18M to $30.50M, driven by clinical trial manufacturing costs.

Cash Position Strengthened Cash and equivalents totaled $119.73M by year-end 2025, supported by recent financing activities.

关注风险

Substantial Funding Required Need substantial additional funding; inability to raise capital forces program delays, reductions, or cessation of operations.

No Product Sales Revenue Limited operating history; no revenue generated from product sales; expecting continued operating losses for foreseeable future.

Clinical Trial Success Dependency Business success depends on clinical trials adequately demonstrating safety and efficacy for aglatimagene and linoserpaturev.

Unpredictable Regulatory Approval Regulatory approval processes are lengthy, complex, and inherently unpredictable, potentially impairing revenue generation.

前瞻展望

Prostate BLA Submission Planned Ongoing dialogue with FDA for aglatimagene BLA submission in prostate cancer targeted for fourth quarter of 2026.

NSCLC Phase 3 Trial Launch Plan to initiate pivotal phase 3 trial for metastatic NSCLC patients resistant to ICI treatment in second quarter of 2026.

Cash Runway Extended Existing cash plus 2026 Follow-On Offering proceeds expected to fund operations into the first quarter of 2028.

Biomarker Data Presentation Expect to present novel immunological biomarker data in localized prostate cancer patients during third quarter of 2026.

同行对比

营业收入 (TTM)

EDIT

$40.52M

+25.4%

PRQR

$17.94M

-15.9%

IMMP

$8.35M

+121.2%

毛利率 (最新季度)

EDIT

100.0%

+2621.3pp

ACIU

100.0%

+0.0pp

PRQR

85.5%

+0.0pp

关键指标

股票代码	市值	市盈率 (TTM)	净资产收益率 (TTM)	负债率
CAPR	$1.59B	-16.1	-67.5%	5.9%
DRTS	$689.12M	-15.7	-57.3%	12.9%
CTNM	$484.25M	-6.7	-30.1%	3.0%

长期趋势

近4季度

营业收入

净利润

经营现金流

4季度营收复合增长率

N/M

营收波动较大

4季度净利润复合增长率

N/M

盈利状态转变

现金流稳定性

现金流需要关注

深度研究

下次财报:2026年5月7日

每股收益:-$0.31

营业收入:-

财务数据

电话会议

财务报告

新闻

利润表

资产负债表

现金流量表

财务比率

变化率

利润表	过去12个月

无数据